Evaluation of hypoglycemic drug-drug interactions by software
-
摘要: 目的 评价并分析不同降糖药物的药物相互作用(DDI)。 方法 将目前临床上常用的降糖药物(包括胰岛素和27种非胰岛素制剂)使用DDI数据库Lexi-InteractionTM分析评价其DDI并进行归纳和排序。 结果 28种药物共涉及DDI数量882种,其中C级最多(69.8%),C、D、X级占总数的91.2%,其中X级为28种。平均每种药物DDI数量最多的为磺脲类药物,其次为二甲双胍,最少的为α-糖苷酶抑制剂。 结论 对于合并用药较多、老年患者及肝肾功能不全者应优先选用DDI数量较少的降糖药物,如α-糖苷酶抑制剂、胰高血糖素样肽-1(GLP-1)类似物、钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)等。Abstract: Objective To evaluate and analyze the drug-drug interactions (DDI) of different antidiabetic drugs. Methods DDI database Lexi-InteractionTM was used to evaluate DDI for 28 commonly used antidiabetic medications (including insulin and 27 non-insulin preparations). Results 882 DDIs were identified for 28 drugs. Category C was the top rated DDI (69.8%). Category C, D, X were accounted for 91.2% of the total DDI. 28 medication combinations belonged to category X, which should be avoided to use together. Sulfonylureas had the most DDI, followed by metformin. Alpha-glucosidase inhibitors had least DDI. Conclusion Hypoglycemic drugs with less DDI, such as α-glycosidase inhibitors, glucagon-likepeptide1(GLP-1)analogs and sodium-dependent glucose transporters 2 inhibitor (SGLT2i)should be considered with high priority for patients taking multiple antidiabetic medications, elderly patients and patients with liver-kidney dysfunction.
-
Key words:
- hypoglycemic drugs /
- drug-drug interactions (DDI) /
- evaluation by software
-
[1] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. Jama, 2013, 310(9):948-959. [2] Doucet J,Chassagne P,Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults:a prospective study of 1000 patients[J]. J Am Geriatr Soc, 1996, 44(8):944-948. [3] Hu DY, Pan CY, Yu JM,et al. The relationship between coronary artery disease and abnormal glucose regulation in China:the China Heart Survey[J]. Eur Heart J, 2006, 27(21):2573-2579. [4] Zhu M, Li J, Li Z, et al. Mortality rates and the causes of death related to diabetes mellitus in Shanghai Songjiang District:an 11-year retrospective analysis of death certificates[J]. BMC Endocr Disord, 2015, 15:45. [5] 应令雯, 周健. 2017年ADA糖尿病医学诊疗标准解读[J]. 中国医学前沿杂志(电子版), 2017, 9(1):48-55. [6] Lien D, Mader TJ. Survival from profound alcohol-related lactic acidosis[J]. J Emerg Med,1999,17(5):841-846. [7] 中国医师协会内分泌代谢科医师分会,中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1):1-10. [8] 母义明, 杨文英, 朱大龙,等. 磺脲类药物临床应用专家共识(2016年版)[J]. 药品评价, 2017, 14(1):5-12. [9] van Giersbergen PL, Treiber A, Clozel M, et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide[J]. Clin Pharmacol Ther,2002,71(4):253-262.
计量
- 文章访问数: 3197
- HTML全文浏览量: 379
- PDF下载量: 698
- 被引次数: 0